Valerie Jansen

Company: Elevation Oncology

Job title: Vice President - Clinical Development

Seminars:

NRG1 fusions: A Tumor-Agnostic Oncogenic Driver 11:00 am

Genomic alterations fall on a spectrum of oncogenic potential. Oncogenic driver alterations are optimal biomarkers for targeted therapy development in precision oncology NRG1 fusions are emerging as potentially actionable oncogenic driver alterations that can be found across solid tumors and may be enriched in certain GI cancers such as pancreatic ductal adenocarcinoma (PDAC) NRG1 fusions…Read more

day: Day One